Chugai Seiyaku Kabushiki Kaisha

F. Hoffmann-la Roche Ag

Yasuo Sugitani

Toshihiko Ohtomo

Takayoshi Tanaka

Ruey-Min Lee

Anton Belousov

Ya-Chi Chen

Gong Chen

Bernhard Reis

Oscar Puig

A method is provided for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or for determining the continuation of GPC3-targeting drug therapy for a patient treated with GPC3-targeting therapy. The method includes determining the number of an immunocyte or an expression level of a molecule expressed on the immunocyte in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the number of the immunocyte or the expression level of the molecule expressed on the immunocyte is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. GPC3-targeting drugs and drug preparations for use according to the disclosed methods are also provided.

GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy

The present invention provides a method for determining the efficacy of a GPC3-targeting therapeutic agent for a liver cancer patient and a GPC3-targeting therapeutic agent or a preparation which is to be administered to a patient for whom it has been determined that the GPC3-targeting therapeutic agent is effective. The present invention provides, for example, a method for determining that a GPC3-targeting therapeutic agent is effective when the expression level of GPC3 per tumor cell is a predetermined value, and a GPC3-targeting therapeutic agent or a preparation which is to be administered to a patient for whom it has been determined that the GPC3-targeting therapeutic agent is effective.

GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective

Growing community of inventors

Tokyo, Japan

Yasuo Sugitani